[PET in gliomas. Overview of current studies]

Area of Science:

• Neuro-oncology
• Medical Imaging
• Nuclear Medicine

Context:

• Gliomas are the most common primary brain tumors, accounting for 30% of intracranial neoplasms.
• Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are primary diagnostic tools, offering detailed morphological information.
• However, conventional imaging has limitations in assessing tumor grade, infiltration, prognosis, and treatment efficacy.

Purpose:

• To explore the role of Positron Emission Tomography (PET) in enhancing glioma diagnosis and management.
• To highlight the utility of various PET tracers for assessing metabolic activity, amino acid uptake, protein synthesis, and proliferation.
• To emphasize the importance of integrating PET findings with morphological imaging.

Summary:

• PET imaging, utilizing tracers like FDG, 11C-methionine, 18F-fluorethyltyrosine, 18F-fluor-deoxyphenylalanine, and 18F-deoxythymidine, provides critical functional and metabolic information about gliomas.
• These PET studies offer insights into glucose metabolism, amino acid uptake, protein synthesis, and cell proliferation, which are not fully captured by CT or MRI.
• The increasing availability of 18F-tracers is expanding the clinical applications of PET in neuro-oncology.
• Coregistration of PET with morphological imaging (CT/MRI) is essential for accurate interpretation, with hybrid PET-MRI systems facilitating this integration.

Impact:

• PET imaging significantly improves the assessment of glioma malignancy grade, tumor infiltration, and differentiation between tumor recurrence and necrosis.
• It provides valuable prognostic information and aids in monitoring treatment response, leading to more personalized patient management strategies.
• The integration of PET with advanced tracers and hybrid imaging technologies represents a significant advancement in the clinical management of glioma patients.